Some thoughts on the Boeing’s criminal settlement, Kamala Harris’ bald-faced lies, a left-wing organization’s diss of the New York Times, and GM CEO Mary Barra becoming the undisputed Queen of Automotive Emissions.
Business
Why U.S. Chief Executives Are Above the Law
Junior Justice Department prosecutors have recommended that Boeing face criminal charges. Here’s why the airplane manufacturer and its management have good reason not to worry.
The Quality Standards of OTC Drug Thieves
Some insights on why shoplifters avoid CVS-branded OTC drugs, the Washington Post and CNN do Al Jazeera proud, another reported major failing of Michigan Gov. Gretchen Whitmer, and an academic validation about why investors should be wary of companies professing the highest morals and ethics.
The Debt Chief Executives Owe Joe Biden
Jeffrey Zients, President Biden’s multimillionaire chief of staff and former Covid czar, recently met privately with America’s most powerful CEOs. Here’s why the CEOs owed Zients a standing ovation.
WaPo Reporters: Legends In Their Own Minds
My contrarian and uncharitable view of what became of the Washington Post under the leadership of recently departed editor Sally Buzbee.
The Undying U.S. Patriotism of Honda and Toyota
Any way you slice it, Honda and Toyota far and away rank as the automakers most loyal to American businesses, workers, and consumers.
Wells Fargo’s Big Brother Mouse Scandal
My thoughts on the latest Wells Fargo wrongdoing, which hasn’t received the critical media attention it deserves.
The Ties That Bind Joe Biden and Donald Trump
Regardless of who wins the presidential election in November, I can promise you this: The rich will continue getting richer while America’s middle class and economically disadvantaged will get poorer.
Shawn Fain’s UAW: America’s Union Disgrace
Given developments and alarming disclosures this week that reflect poorly on UAW president Shawn Fain, workers would be wise to steer clear of the union under his leadership.
Beware of CVS-Branded Over-the-Counter Drugs!
Reading Bloomberg’s frightening analysis of CVS-branded medicines, I’m opting to pay more for name brand OTC drugs. My guess is that if you become aware of Bloomberg’s findings, so will you.